Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 20 2024
0mins
Source: Newsfilter
Financial Position and Strategic Initiatives: Synaptogenix, Inc. reported having $19.6 million in cash as of September 30, 2024, and is forming a Special Committee to explore strategic opportunities aimed at enhancing investor value while expecting a reduced cash burn rate.
Drug Development Focus: The company is considering advancing its Bryostatin-1 asset in collaboration with third-party partners and has submitted a grant proposal to the NIH for its development, while also highlighting its previous research on neurodegenerative diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
